Patents Examined by Mary Beth Tung
  • Patent number: 6610297
    Abstract: Disclosed are compositions for treating allergies that include either BSW17 mimotope peptides or antibodies raised against BSW17 mimotope peptides. Also disclosed are methods for the treatment of allergies which involve administration of BSW17 mimotope peptides or the administration of antibodies raised against BSW17 mimotope peptides.
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: August 26, 2003
    Assignee: Novartis AG
    Inventors: Franz Kricek, Beda Stadler
  • Patent number: 6403092
    Abstract: Activation of &agr;2-macroglobulin (&agr;2M) with a nucleophilic compound followed by incubation of the activated &agr;2M at elevated temperature with a biomolecule results in covalent incorporation of the intact biomolecule into the &agr;2M molecule, without the use of proteinases. The thus-formed structurally defined and stable complex may be used as an antigen for stimulating the immune response, for example, in the form of a vaccine. Enhanced antigen presentation of a particular biomolecule is provided, especially for those that are poorly immunogenic; reduction of the immunodominance of particular epitopes is also provided.
    Type: Grant
    Filed: March 31, 1999
    Date of Patent: June 11, 2002
    Assignee: Duke University
    Inventors: Salvatore Pizzo, Hanne Grøn
  • Patent number: 6387613
    Abstract: The invention provides a human short-chain dehydrogenase (HSCD) and polynucleotides which identify and encode HSCD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HSCD.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: May 14, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Preeti Lal, Neil C. Corley
  • Patent number: 6368636
    Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: April 9, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
  • Patent number: 6361939
    Abstract: Polynucleotides encoding various dendritic cell specific proteins from a primate are provided. Uses of purified sequences are also disclosed, including producing related reagents, e.g., specific antibodies, and purified proteins. Methods of using these reagents and related diagnostic kits are also described.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: March 26, 2002
    Assignee: Schering Corporation
    Inventors: Elizabeth Esther Mary Bates, Blandine Marie de Saint-Vis, Christophe Caux, Serge J. E. Lebecque, Jacques Banchereau
  • Patent number: 6361954
    Abstract: The invention pertains to novel genes which function in the regulation of DNA replication and/or entry of a cell into mitosis. Tile invention also pertains to novel proteins encoded by the genes described herein, antibodies which bind the encoded protein, and homologs of the novel genes which function in regulation of DNA replication and/or entry of a cell into mitosis find hybridize to the DNA sequence of the novel genes. The invention also includes methods for determining the presence of a proliferative disorder comprising determining the presence of level of hscdc6.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: March 26, 2002
    Assignees: Cold Spring Harbor Laboratory, The University of Texas System
    Inventors: Bruce Stillman, R. Sanders Williams, Juan R. Mendez
  • Patent number: 6355248
    Abstract: Methods and compositions for modulating an immune response in a mammal infected with a bacterium, a virus, or a parasite are provided. The methods and compositions are useful in mammals experiencing an acute infection and in mammals experiencing a chronic infection. The methods and compositions may be used in conjunction with a known treatment for infection of a mammal by an infectious agent. Methods and compositions for transmucosal delivery of a molecule comprising an epitope located in close proximity to the immune response are provided.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: March 12, 2002
    Assignee: Thomas Jefferson University
    Inventors: Frank Michaels, Timothy Block
  • Patent number: 6342344
    Abstract: The present invention relates to an antibody composition which contains antibodies directed to murine leukocyte and murine erythroid cells. This composition is used in a novel negative selection process to enrich for human hematopoietic cells from a sample from human-murine chimeric mice. The invention also relates to kits for carrying out this process.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: January 29, 2002
    Assignee: StemCell Technologies Inc.
    Inventors: Terry E. Thomas, Connie J. Eaves
  • Patent number: 6338942
    Abstract: Methods and systems are provided for the selective expansion of target cell populations, and methods of treating patients with cell populations and products.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: January 15, 2002
    Assignee: T. Breeders, Inc.
    Inventors: Morey Kraus, Paul T. Wilder, Jill Friberg
  • Patent number: 6335195
    Abstract: The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AI); AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists, either alone or in combination with other growth factors and cytokines.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: January 1, 2002
    Assignee: Maret Corporation
    Inventors: Kathleen E. Rodgers, Gere S. DiZerega
  • Patent number: 6333171
    Abstract: The present invention relates to compositions and methods for the expression of nucleic acids or polypeptides into mature T lymphocytes. The invention relates more specifically to methods of selective gene expression into mature T lymphocytes, based on CD4-derived regulatory sequences, such as CD4-derived enhancer sequences. The invention is particularly suited for regulating gene expression into mature T lymphocytes in vitro, ex vivo or in vivo, upon genetic modification of hematopoietic precursors and maturation thereof.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: December 25, 2001
    Assignee: Universite Pierre et Marie Curie
    Inventors: David Klatzmann, Patrick Salmon, Olivier Boyer
  • Patent number: 6328960
    Abstract: Disclosed is a method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: December 11, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
  • Patent number: 6329517
    Abstract: The present invention relates to a dermatomyositis-specific auto-antigen, a DNA encoding it and a process for the preparation thereof as well as its use.
    Type: Grant
    Filed: January 12, 1998
    Date of Patent: December 11, 2001
    Assignee: Privates Institut für Imonologie und Molekulargenetik GmbH
    Inventors: Hans Peter Seelig, Manfred Renz
  • Patent number: 6328962
    Abstract: Antibody molecules specific for surface structures of antigen presenting cells that have been modified to include an antigen moiety at a specific site therein to produce novel conjugate antibody molecules are disclosed. These conjugate molecules are produced by genetic modification of genes encoding light and heavy chains of the surface structure specific antibody, and expression in mammalian cells to produce the conjugate antibody. The conjugate antibody retained specificity for antigen presenting cells and contained the antigen moiety. The conjugate antibody molecules deliver the antigen to antigen presenting cells to produce an enhanced immune response to a host immunized therewith. The conjugate antibody molecules and nucleic acid molecules encoding them are useful as antigens and as immunogens in diagnostic and prophylactic applications.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: December 11, 2001
    Assignee: Aventis Pasteur Limited
    Inventors: Naveen N. Anand, Brian H. Barber, George A. Cates, Judith E. Caterini, Michel H. Klein
  • Patent number: 6329159
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: December 11, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Patent number: 6326004
    Abstract: Antiviral methods comprising contacting human rhinovirus with tICAM(453).
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: December 4, 2001
    Assignee: Bayer Corporation
    Inventors: Jeffrey M. Greve, Alan McClelland, Gary Davis
  • Patent number: 6326354
    Abstract: A novel p15 BID polypeptide having cell death agonist activity is disclosed. The p15 BID polypeptide is produced by caspase-cleavage of BID in cells undergoing cell death mediated by TNF or FAS receptors. The p15 BID is useful in methods for modulating death of a target cell which comprise treating the cell with p15 BID. Methods for inhibiting cell death are also described which involve treating a target cell with a mutant p15 BID lacking cell death agonist activity.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: December 4, 2001
    Assignee: Washington University
    Inventors: Atan Gross, Stanley J. Korsmeyer
  • Patent number: 6310195
    Abstract: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof, or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: October 30, 2001
    Assignee: ImClone Systems Incorporated
    Inventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore
  • Patent number: 6309637
    Abstract: The invention provides a human microfibril-associated glycoprotein 4 splice variant (MAG4V) and polynucleotides which identify and encode MAG4V. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of MAG4V.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: October 30, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Y. Tom Tang, Neil C. Corley, Purvi Shah
  • Patent number: 6309825
    Abstract: According to the present invention there is provided an agent and method of detecting 8-oxoquanine, 8-oxodeoxyguanosine, 8-oxoadenine, and 8-oxodeoxyadenosine.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: October 30, 2001
    Assignee: University of Leicester
    Inventor: Siâ ;n Myra Thomas